Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | NMRA |
---|---|---|
09:32 ET | 5398 | 12.75 |
09:34 ET | 3030 | 12.73 |
09:36 ET | 1484 | 12.81 |
09:38 ET | 2461 | 12.8 |
09:39 ET | 10647 | 12.8752 |
09:41 ET | 508 | 12.94 |
09:43 ET | 712 | 13.08 |
09:45 ET | 10172 | 12.985 |
09:48 ET | 1100 | 13 |
09:50 ET | 857 | 12.915 |
09:52 ET | 1576 | 13.005 |
09:54 ET | 2865 | 12.995 |
09:56 ET | 50922 | 13.02 |
09:59 ET | 2044 | 12.99 |
10:01 ET | 858 | 12.985 |
10:03 ET | 600 | 12.98 |
10:06 ET | 40910 | 13.005 |
10:08 ET | 100 | 13.01 |
10:10 ET | 2126 | 13.01 |
10:12 ET | 2476 | 13 |
10:14 ET | 5193 | 13.05 |
10:15 ET | 5825 | 12.98 |
10:17 ET | 33900 | 13 |
10:19 ET | 751 | 13 |
10:21 ET | 1450 | 12.99 |
10:24 ET | 2000 | 13.005 |
10:26 ET | 3014 | 13.02 |
10:28 ET | 200 | 13.04 |
10:30 ET | 426 | 13.045 |
10:32 ET | 488 | 13.08 |
10:33 ET | 4804 | 13.21 |
10:35 ET | 4545 | 13.1 |
10:37 ET | 300 | 13.1 |
10:39 ET | 4002 | 13.08 |
10:42 ET | 1900 | 13.15 |
10:44 ET | 4988 | 13.12 |
10:46 ET | 304 | 13.025 |
10:50 ET | 2729 | 13.07 |
10:51 ET | 244 | 13.07 |
10:53 ET | 200 | 13.04 |
10:57 ET | 1600 | 13.065 |
11:00 ET | 4293 | 13.01 |
11:02 ET | 2805 | 13.06 |
11:04 ET | 4522 | 13.09 |
11:06 ET | 940 | 13.1 |
11:09 ET | 2270 | 13.1 |
11:11 ET | 500 | 13.15 |
11:13 ET | 5830 | 13.105 |
11:18 ET | 1300 | 13.13 |
11:20 ET | 1719 | 13.185 |
11:22 ET | 500 | 13.18 |
11:24 ET | 2576 | 13.205 |
11:26 ET | 100 | 13.205 |
11:27 ET | 1100 | 13.18 |
11:29 ET | 1046 | 13.18 |
11:31 ET | 200 | 13.17 |
11:33 ET | 600 | 13.16 |
11:36 ET | 1000 | 13.14 |
11:38 ET | 1475 | 13.2 |
11:40 ET | 20826 | 13.25 |
11:42 ET | 2913 | 13.25 |
11:44 ET | 2676 | 13.22 |
11:45 ET | 700 | 13.25 |
11:47 ET | 46177 | 13.26 |
11:49 ET | 1364 | 13.25 |
11:51 ET | 2796 | 13.17 |
11:54 ET | 300 | 13.15 |
11:56 ET | 900 | 13.15 |
11:58 ET | 1146 | 13.18 |
12:00 ET | 521 | 13.16 |
12:02 ET | 7100 | 13.25 |
12:03 ET | 800 | 13.22 |
12:05 ET | 600 | 13.26 |
12:07 ET | 5761 | 13.245 |
12:09 ET | 58527 | 13.3 |
12:12 ET | 450 | 13.245 |
12:14 ET | 2480 | 13.24 |
12:16 ET | 200 | 13.24 |
12:18 ET | 1407 | 13.24 |
12:20 ET | 774 | 13.225 |
12:21 ET | 500 | 13.22 |
12:23 ET | 400 | 13.21 |
12:25 ET | 600 | 13.22 |
12:27 ET | 3796 | 13.29 |
12:30 ET | 300 | 13.26 |
12:32 ET | 1150 | 13.2491 |
12:34 ET | 200 | 13.295 |
12:36 ET | 201 | 13.27 |
12:38 ET | 800 | 13.275 |
12:39 ET | 500 | 13.26 |
12:45 ET | 1300 | 13.27 |
12:48 ET | 2177 | 13.25 |
12:50 ET | 11588 | 13.245 |
12:52 ET | 2935 | 13.26 |
12:54 ET | 100 | 13.245 |
12:56 ET | 300 | 13.24 |
12:57 ET | 502 | 13.23 |
12:59 ET | 400 | 13.25 |
01:01 ET | 500 | 13.24 |
01:03 ET | 200 | 13.24 |
01:06 ET | 600 | 13.25 |
01:08 ET | 1395 | 13.24 |
01:10 ET | 1450 | 13.26 |
01:12 ET | 100 | 13.25 |
01:14 ET | 644 | 13.24 |
01:15 ET | 3632 | 13.195 |
01:17 ET | 1800 | 13.17 |
01:19 ET | 2036 | 13.18 |
01:21 ET | 1300 | 13.18 |
01:24 ET | 300 | 13.185 |
01:26 ET | 100 | 13.17 |
01:28 ET | 100 | 13.17 |
01:30 ET | 8132 | 13.18 |
01:32 ET | 7702 | 13.1 |
01:33 ET | 4312 | 13.13 |
01:35 ET | 200 | 13.14 |
01:37 ET | 289 | 13.15 |
01:39 ET | 300 | 13.15 |
01:44 ET | 600 | 13.16 |
01:46 ET | 200 | 13.14 |
01:48 ET | 691 | 13.15 |
01:50 ET | 100 | 13.14 |
01:51 ET | 1291 | 13.195 |
01:53 ET | 800 | 13.2 |
01:57 ET | 900 | 13.2 |
02:00 ET | 1468 | 13.2 |
02:02 ET | 300 | 13.195 |
02:04 ET | 800 | 13.205 |
02:06 ET | 313 | 13.2 |
02:09 ET | 1712 | 13.17 |
02:11 ET | 1900 | 13.17 |
02:13 ET | 1200 | 13.11 |
02:15 ET | 1460 | 13.055 |
02:18 ET | 604 | 13.05 |
02:20 ET | 1626 | 13.03 |
02:22 ET | 7755 | 13.12 |
02:24 ET | 1207 | 13.06 |
02:26 ET | 2121 | 13.02 |
02:27 ET | 300 | 13.03 |
02:29 ET | 500 | 12.99 |
02:31 ET | 400 | 13.005 |
02:33 ET | 1350 | 12.95 |
02:36 ET | 900 | 13 |
02:38 ET | 600 | 13.01 |
02:40 ET | 900 | 13.04 |
02:42 ET | 1137 | 13.08 |
02:44 ET | 847 | 13.07 |
02:45 ET | 5224 | 13.07 |
02:47 ET | 1433 | 13.05 |
02:49 ET | 1950 | 13.06 |
02:51 ET | 6439 | 13.06 |
02:54 ET | 13901 | 13.05 |
02:56 ET | 350 | 12.98 |
02:58 ET | 1650 | 12.99 |
03:00 ET | 100 | 12.995 |
03:02 ET | 700 | 12.95 |
03:03 ET | 534 | 12.95 |
03:05 ET | 910 | 12.96 |
03:09 ET | 300 | 12.95 |
03:12 ET | 300 | 12.94 |
03:14 ET | 1789 | 12.93 |
03:16 ET | 850 | 12.95 |
03:18 ET | 2052 | 12.96 |
03:20 ET | 7176 | 13 |
03:21 ET | 1000 | 13 |
03:23 ET | 3946 | 13 |
03:25 ET | 2750 | 13 |
03:27 ET | 3134 | 13 |
03:30 ET | 1345 | 12.995 |
03:32 ET | 6792 | 12.95 |
03:34 ET | 2443 | 12.95 |
03:36 ET | 6107 | 13 |
03:38 ET | 2168 | 13 |
03:39 ET | 8442 | 13.05 |
03:41 ET | 7880 | 13.07 |
03:43 ET | 2938 | 13.07 |
03:45 ET | 1850 | 13.12 |
03:48 ET | 3850 | 13.15 |
03:50 ET | 3599 | 13.15 |
03:52 ET | 3742 | 13.19 |
03:54 ET | 81276 | 13.16 |
03:56 ET | 9275 | 13.17 |
03:57 ET | 39044 | 13.16 |
03:59 ET | 177169 | 13.21 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Neumora Therapeutics Inc | 1.9B | -7.9x | --- |
Akero Therapeutics Inc | 1.9B | -8.4x | --- |
Soleno Therapeutics Inc | 2.1B | -20.8x | --- |
Vera Therapeutics Inc | 2.1B | -20.1x | --- |
Rocket Pharmaceuticals Inc | 1.8B | -6.6x | --- |
Edgewise Therapeutics Inc | 1.8B | -17.4x | --- |
Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company’s therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Its other candidates include NMRA-266, NMRA-511, and NMRA-NMDA. NMRA-266 is a positive allosteric modulator program of the M4 muscarinic receptor (M4R) for the treatment of schizophrenia. NMRA-266 is designed to be selective for the M4 receptor subtype of the muscarinic receptor family. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR). NMRA-NMDA is an NMDA positive allosteric modulator program that the Company is developing for the treatment of schizophrenia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.1B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 160.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.66 |
Book Value | $2.95 |
P/E Ratio | -7.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.